https://www.selleckchem.com/pr....oducts/Tebipenem-piv
6±2.0mmol/l) with 67.1% in the target range during Ramadan. The incidence of hypoglycemia in the whole group (2.9 v 2.9) and in the SU+ (3.7 vs 3. and BI+ (1.7 vs 2.9) groups and eHbA1c (P=0.56, P=0.93), average glucose (P=0.56, P=0.92) and time within range (P=0.63, P=0.73) did not change in the SU+ and BI+ groups, respectively, before and during Ramadan. Structured education with adjustment of the dose of glucose lowering medication alongside use of the FGMS can effectively mitigate the increased risk of hypoglycemi